ESC 2021

Episodes 1-13 of 13

Implementation of salt substitution strategies
Implementation of salt substitution strategies
ESC 2021
Implementation of salt substitution strategies
- Prof. Barbara Casadei, MD
NOAC as possible treatment option in patients with AF after successful TAVI
NOAC as possible treatment option in patients with AF after successful TAVI
ESC 2021
NOAC as possible treatment option in patients with AF after successful TAVI
- Prof. Nicolas van Mieghem, MD, PhD
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
ESC 2021
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
- Prof. Freek Verheugt, MD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
ESC 2021
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
- Prof Bertram Pitt
Switching to a salt substitute reduces risk of stroke, CV events and death
Switching to a salt substitute reduces risk of stroke, CV events and death
ESC 2021
Switching to a salt substitute reduces risk of stroke, CV events and death
- Prof. Bruce Neal, MD, PhD
Moving the field of medicine and science is a collective exercise
Moving the field of medicine and science is a collective exercise
ESC 2021
Moving the field of medicine and science is a collective exercise
- Prof. Stephan Achenbach, MD
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
ESC 2021
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
- Prof. Stefan Anker, MD, PhD
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
ESC 2021
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
- Prof. Frank Ruschitzka, MD
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
ESC 2021
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
- Prof. Rudolf de Boer
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
ESC 2021
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
- Kevin Damman, MD, PhD
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
ESC 2021
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
- Milton Packer, MD
What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?
What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?
ESC 2021
What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?
- Prof. Carolyn Lam, MD
Another chapter in the SGLT2i book
Another chapter in the SGLT2i book
ESC 2021
Another chapter in the SGLT2i book
- Prof. Rudolf de Boer

Episodes 1-13 of 13

Title

Share on ReachMD